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Abstract
Background: Hepatitis C virus (HCV) genotyping is the most significant predictor of the response to antiviral therapy. The
aim of this study was to develop and evaluate a novel real-time PCR method for HCV genotyping based on the NS5B region.
Methodology/Principal Findings: Two triplex reaction sets were designed, one to detect genotypes 1a, 1b and 3a; and
another to detect genotypes 2a, 2b, and 2c. This approach had an overall sensitivity of 97.0%, detecting 295 of the 304
tested samples. All samples genotyped by real-time PCR had the same type that was assigned using LiPA version 1 (Line in
Probe Assay). Although LiPA v. 1 was not able to subtype 68 of the 295 samples (23.0%) and rendered different subtype
results from those assigned by real-time PCR for 12/295 samples (4.0%), NS5B sequencing and real-time PCR results agreed
in all 146 tested cases. Analytical sensitivity of the real-time PCR assay was determined by end-point dilution of the 5000 IU/
ml member of the OptiQuant HCV RNA panel. The lower limit of detection was estimated to be 125 IU/ml for genotype 3a,
250 IU/ml for genotypes 1b and 2b, and 500 IU/ml for genotype 1a.
Conclusions/Significance: The total time required for performing this assay was two hours, compared to four hours
required for LiPA v. 1 after PCR-amplification. Furthermore, the estimated reaction cost was nine times lower than that of
available commercial methods in Brazil. Thus, we have developed an efficient, feasible, and affordable method for HCV
genotype identification.
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Introduction
Hepatitis C virus (HCV) genotyping is reported to be the
primary tool for assessing the course of infection and determining
treatment duration [1]. Several molecular methods targeting
different HCV genomic regions have been described for
determining genotype [2,3]. Most commercial methods target
the 59 untranslated region (59UTR), which is the region of choice
for qualitative and quantitative HCV RNA detection because of its
high degree of conservation among different subtypes [4]. The 59
UTR, however, does not allow sufficient discrimination between
closely related subtypes within the same genotype. Subtyping is
particularly useful for investigating infection outbreaks and for
better understanding the epidemiological and virological features
of HCV [5]. In addition, accurate subtyping may be important for
future studies aiming to develop new drugs and to increase our
understanding of how HCV becomes resistant to therapies [6].
Sequencing of an appropriate coding region, such as the
nonstructural 5B region (NS5B), core, or E1 is the gold standard
for discriminating HCV types and subtypes [7]. Despite of the
usefulness of this approach, sequencing is a laborious technique
and typically requires several sample handling steps. This increases
turnaround time, thus impairing patient diagnosis and treatment.
Methods such as real-time PCR are specific and sensitive
because they simultaneously use probes and primers to detect
target sequences [8]. Moreover, this technique is performed on an
automated platform without the need for post-PCR procedures,
thus minimizing cross-contamination between samples and
accelerating the analysis. The aim of this study was to develop,
standardize and validate a method for identifying HCV geno-
types by real time PCR based on the analysis of the HCV NS5B
region.
Results
We have designed and standardized a new real-time PCR-based
method for genotyping HCV. This method consists of two triplex
reactions targeting genotypes 1, 2 and 3. Both reverse transcrip-
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10150tion and amplification were carried out in the same reaction tube,
as detailed in Figure 1.
Real-Time PCR genotyping validation tests
Accuracy. Results obtained by real-time PCR genotyping
and partial sequencing of the NS5B region showed 100%
concordance in all 146 tested samples. No discrepancies were
found using phylogenetic analysis or matching with Blast.
Reproducibility. Assays were performed for genotypes 1a,
1b, and 3a on three different days with 16 replicates (n=48) of
each genotype/sample. The total coefficient of variation of the
cycle threshold (Ct) was 2.67% for genotype 3a (mean Ct,
27.4960.73), 6.25% for genotype 1b (mean Ct, 26.5461.66), and
6.40% for genotype 1a (mean Ct, 27.6561.73).
Sensitivity. Analytical sensitivity was determined by
analyzing the OptiquantH HCV RNA Quantification Panel
(Acrometrix, Benicia, CA, USA). The 95% detection limit was
measured at 250 IU/ml. Relative sensitivity based on patients
infected with genotypes 1a, 2b, or 3a showed a 95% detection limit
of 500 IU/ml for genotype 1a, 250 IU/ml for genotype 2b, and
125 IU/ml for genotype 3a.
Specificity. Based on 53 blood donor samples, when the two
primer-probe sets were used for real-time PCR genotyping, no
false-positive reactions were detected. Analytical specificity was
Figure 1. Schematic view of modified one-step real-time PCR. The reaction mix was prepared in two fractions, in tubes and caps.
doi:10.1371/journal.pone.0010150.g001
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with genotypes 4a and 5a. No false-positive results were obtained
when those genotypes were tested with each genotype-specific
primer-probe set. Based on 40 samples from patients with diseases
unrelated to HCV, the two primer-probe sets were found to be
adequately specific, not leading to false-positive results with
common hepatitis viruses (HAV and HBV), dengue virus or HIV.
In vitro mixed infections
After testing in vitro prepared mixtures containing different
proportions of RNA of genotypes 1a and 3a, both genotypes were
correctly detected in all the tested mixtures.
Correlation between real-time PCR genotyping and LiPA
A total of 304 clinical samples were used to compare the real-
time PCR genotyping with LiPA v. 1 (Table 1). Of those, nine
samples could not be amplified and genotyped by real-time PCR,
leading to 3% of false-negative results. Of the remaining 295
samples, genotyping by real-time PCR detected 100% (184/184)
of the samples assigned as genotype 1 by LiPA v. 1. Mean Ct of
real-time PCR genotyping for genotype 1a was 26.43 and 27.24
for genotype 1b. Real-time PCR genotyping also produced
concordant results for all the 31 samples classified as genotype 2
by LiPA v. 1, with mean Ct’s of 25.83. Moreover, real-time PCR
was able to genotype 80/80 (100%) samples of genotype 3 with
mean Ct’s of 26.34. At the type level, a concordance of 100% was
observed for the 295 samples when real-time PCR genotyping and
LiPA v. 1 were compared. In contrast, when we compared the
results of the two methods at the subtype level, the real-time PCR
test was able to subtype the 68 samples non-subtyped by LiPA v. 1,
as detailed in Table 1. Of those, 55 (80.9%) were sequenced and
the results assigned by real-time PCR were confirmed.
Subtype classification discrepancies were found in 4.0% (12/
295) of the samples. The genotyping concordance between real-
time PCR and LiPA v. 1 was moderate (k coefficient=0.1111,
P=0,2218) when discrepant and non-subtyped results were taken
into account. Ten of the 12 (83.3%) samples with discrepant
subtyping results were sequenced and the results obtained from
real-time PCR genotyping were confirmed.
Estimation of costs
When the costs related to the real-time PCR-based genotyping
test were compared to those of LiPA v. 1, a calculated nine-time
decrease of unitary test cost estimation was observed.
Discussion
In this study we described the development of a novel HCV
genotyping method based on real-time PCR that involves two one-
step triplex reactions. One reaction detects genotypes 1a, 1b, and
3a; while the other detects genotypes 2a, 2b, and 2c. The present
method targets the NS5B region, which may be useful for
epidemiological studies as well as for correlating patient response
to current and new drugs as a function of infection with different
HCV types and subtypes. Accuracy, precision, analytical and
relative sensitivity and specificity were investigated in order to
validate the method. Performance was evaluated by comparing the
genotyping results obtained from real-time PCR with those
generated by LiPA v. 1 and partial NS5B sequencing.
Some studies have reported real-time PCR methods for HCV
genotyping. Two studies have described a single-step, real-time,
reverse transcription-PCR (RT-PCR) reaction using a genotype-
specific hydrolysis probe [9],[10], LightCycler probes [11],[12] or
SYBR Green detection [13]. All these methods focus on the 59
UTR. More recently, a real-time PCR-based method has become
commercially available (Abbott HCV Genotype ASR). The assay
design of this kit is such that genotypes 1a and 1b are typed by
amplification targeting in the NS5B region. Other genotypes such
as 2, 3, 4, 5, and 6 are detected through the 59 UTR. Cook [14]
compared this commercial method with a restriction fragment
polymorphism (RLFP) method and discrepant samples were
sequenced. Results showed the analytical sensitivity to be poor
for genotypes 1a and 1b, even when these were present at
.1500 UI/ml. In contrast, our method shows a lower limit of
detection in the genotype-specific reactions ranging from 125 IU/
ml for genotype 3a, to 500 IU/ml for genotype 1a. The current
genotyping method presented an overall detection rate of 295/304
(97.0%), which is similar to previously reported PCR-based
methods [3].
It has been demonstrated that there is no difference in the
relative efficiency of one-step and two-step systems when the
expression rate of the target gene is high [3]. When the rate of
expression is low, however, detection occurred five PCR cycles
earlier in the one-step method than in the two-step method. Based
on these findings, we sought to standardize our method as a one-
step system instead of a two-step one. The next step was to choose
an enzyme that could work at higher temperatures in the reverse
transcription reaction. Different studies show that the choice of
enzyme is a key determinant of reaction efficiency [15],[16].
In this study, we used a one-step kit with Superscript
TM III, a
modified version of MMLV-RT that is stable at 45–60uC; the use
of these elevated temperatures reduces the formation of secondary
structures and the RNase H activity associated with the reverse
transcriptase [17].
Studies have shown that addition of forward primers after the
reverse transcription reaction and before activation of Taq DNA
polymerase prevents the formation of primer-dimers and results in
more efficient amplification [16]. We therefore tested a reaction
modification in which the reagents were added separately. Some of
the reagents were placed in the reaction tube and the remaining
reagents, including the forward primer, were placed in the tube
caps and spun into the reaction tubes after the completion of the
reverse transcription step. The modified one-step method showed
earlier amplification (5.6 Ct’s on average) than the original one-
Table 1. Comparison of the HCV genotyping results obtained
with LiPA version 1 (59UTR) and Real-Time PCR genotyping
(NS5B).
LiPA
(59UTR) Real-time PCR genotyping (NS5B)
1a 1b 2a 2b 2c 3a Negative Total
13 5
35 71 4 3
35
1a 47 5
3 52
3
1b 7
5 75 3 85
5
1a/1b 4
4 4
3 8
7
21 1 4
11 41 9
11
2a/2c 3
2 14
2
2b 13 13
3a 80 80
95
44 89
6 12 7
11 3
2 80 9 Total
Superscript data represent the number of samples sequenced and confirmed
by NS5B partial sequencing.
doi:10.1371/journal.pone.0010150.t001
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optical cap, the reaction could be carried out without opening the
tube, thereby avoiding potential contamination between samples
and enabling the reaction to be performed in a single step.
The cost-benefit of a triplex reaction was also considered when
setting up the assay. Therefore, a single primer set was designed to
amplify genotypes 1a, 1b and 3a. Probes labeled with the
fluorophores FAM, VIC and NED, which use different optical
reading channels, were used to detect PCR products. An
equivalent triplex reaction was set to detect subtypes 2a, 2b, and
2c, and the melting temperature was calculated to be 60uC for
primers and 70uC for probes.
To avoid the inclusion of polymorphic positions within the
NS5B region, shorter oligonucleotides were designed into the
probes of genotypes 1a, 1b, and 3a. Consequently, the estimated
melting temperature was 66uC for probes and 56uC for primers,
and an additional cycling step of 50uC was added to the real-time
PCR. The above types and subtypes were selected because they
account for 99% of the HCV-infected population in Brazil [18]. In
contrast, genotypes 4 and 5 account for 0.3% of the Brazilian cases
[19] and genotype 6 has never been described in Brazil [20].
A recent study of real-time PCR genotyping has proposed
extracting RNA from a plasma volume of 1,000 ml eluting it into
80 ml, which corresponds to a 12.5-fold concentration [14]. In the
present study, because of the limited amount of plasma available to
us, we extracted RNA from 200 ml of plasma and eluted it into 60 ml,
corresponding to a 3.3-fold concentration. The lower concentration
was compensated by adding 19 mlo fR N At ot h er e a c t i o n .
Validation tests confirmed the specificity of the present method,
both in relation to different genotypes and to the potential
presence of a mixed viral population. Results showed that this
method can detect multiple genotypes at all dilutions tested, even
when the minor genotype is present at 10-fold lower levels than the
major genotype. However, more samples must be analyzed in
order to determine the true prevalence of mixed infections in our
population.
When HCV genotyping results generated by real-time PCR and
LiPA v. 1 were compared, 100% concordance was found at the
type level. These results are similar to those reported by previous
study involving 357 samples from blood donors in France, which
demonstrated 100% concordance between 59 UTR and NS5B
sequence analysis when classifying types [4]. However, genotype
identification based on the 59 UTR may pose a problem in some
geographical regions, because some genotype 6 variants found in
Southeast Asia have identical 59 UTR sequences to those of
genotypes 1a or 1b [3].
At the subtype level, however, LiPA v. 1 was unable to subtype
68 of the 295 samples (23.0%), all of which were correctly typed by
real-time PCR as confirmed by sequencing. A misclassification
frequency of 4.0% (12/295) was observed when comparing the
genotyping results of real-time PCR and LiPA v. 1. This lack of
agreement includes cases in which the two methods gave different
subtype results. In this study, LiPA v. 1 misclassified seven samples
of genotype 1a as genotype 1b, yielding a misclassification rate of
12.9% for subtype 1a. This finding is consistent with other study
that have found that amplifying the 59 UTR overestimates the
frequency of subtype 1b by 20% at the expense of subtype 1a [21].
Furthermore, LiPA v. 1 was unable to assign the subtype for eight
samples which were typed as 1a/1b. Using real-time PCR
genotyping, four of these samples were classified as 1b and the
remaining four as genotype 1a.
The real-time PCR genotyping method described herein
showed high accuracy at the subtype level but failed to amplify
3% of the samples. These results show that targeting a
polymorphic region potentially impairs amplification efficiency
since potential mutations may reduce the affinity between the
target region and the PCR primers and probes.
In addition to its robustness, the real-time PCR method costs 9
times less than the commercial methods currently available in
Brazil, when the costs of reagents and laboratory material are
taken into account. Another positive feature of our proposed
method is its fewer handling steps and its faster turnaround time.
Since in Brazil the prevalence of genotypes 4 and 5 is low while
genotype 6 has never been described, those types were not taken
into account when designing this method. However, the same
detection platform described herein can be used to design
complementary assays to detect genotypes 4, 5 and 6.
This method may provide more accurate correlation between
clinical outcomes and different genotypes and their subtypes, as
well as improved understanding of the role of genomic variability
on HCV infectiousness and on its demographic pattern of
infection.
Materials and Methods
Sample selection
Ethylenediaminetetraacetic acid (EDTA) plasmawas prospectively
collected between January 2005 and February 2008 from 304
patients chronically infected with HCV who were admitted to the
Parana ´ State Reference Laboratory of Health (LACEN-PR) and the
Clinics Hospital at the University of Sa ˜o Paulo. Plasma was stored at
270uC until use. Sample selection was based on HCV genotype as
had been previously assigned using the Versant
TM HCV genotype
Assay-LiPA (version I; Siemens Medical Solutions, Diagnostics
Division, Fernwald, Germany). The study protocol was approved
by the Ethics Committee of University of Sa ˜o Paulo (CAAE –
2546.0.015.000-05). The requirement for written informed consent
was waived by the IRB because the samples used were coded upon
collection and storage. Besides, the study did not present any risks for
the patients and involved no procedures for which written consent is
normally required outside of the research context.
RNA extraction
A total of 200 ml of EDTA plasma was extracted using the
automated platform Nuclisens easyMAG (bioMe ´rieux, Boxtel,
Netherlands) according to the manufacturer’s instructions. The
RNA was eluted in 60 ml of elution buffer. The total RNA was
quantified using the Quant-iT
TM RNA assay kit (Invitrogen,
Carlsbad, CA, USA). The observed mean quantity was 30,6 ng.
Real-time PCR genotyping
Primers were designed to anneal to conserved sites within the
NS5B region and probes were designed to target the internal
polymorphic positions in this genomic region. Oligonucleotide
design was based on the analysis of data provided by the Los
Alamos National Laboratory (http://hcv.lanl.gov/components/
hcv-db/GET_ALIGNMENTS/get_alignment.comp).
One primer pair and three different probes labeled with
different fluorophores were designed to amplify and detect
genotypes 1a, 1b, and 3a. An equivalent strategy was used to
detect genotypes 2a, 2b, and 2c. Sequences, locations and
specificities of primers and probes are shown in Table 2.
Oligonucleotide melting temperatures were calculated using
Primer Express (Applied Biosystems, Foster, CA, USA).
Modified one-step real-time PCR
Reactions were performed in a final volume of 50 ml using the
Superscript
TM III PlatinumH one-step quantitative RT-PCR
HCV Genotyping — Real-Time PCR
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fractions. The first fraction (F1) consisted of 18.5 ml of 2X reaction
mix (6 mM MgSO4, and 0.4 mM of each dNTP), 1.0 mlo fTaq
mix (Superscript
TMIII RT, Platinum Taq Mix), 200 nM of reverse
primer (R56_1–3 or gen2RSN), and 0.5 ml of RNase Out
(Invitrogen). Twenty-one microliters of F1 were added to optical
tubes. The second reaction mix fraction (F2) consisted of 4.4 mlo f
2X reaction mix, 200 nM of forward primer (F56_1–3 or
gen2FSN), 1.5 ml of 50 mM MgSO4, 0.1 ml of ROX (25 mM),
and 200 nM of each probe (against either genotypes 1a, 1b, and
3a; or against genotypes 2a, 2b, and 2c). A final F2 volume of 10 ml
was transferred to the caps of the optical tubes. After the addition
of 19 ml of RNA, the optical tubes (containing F1) were carefully
covered with the caps (containing F2). Reverse transcription was
carried out in a GeneAmp PCR System 9700 (Applied Biosystems)
for 35 min at 50uC with the thermocycler cover open. Afterwards,
tubes were briefly centrifuged and real-time PCR was carried out
in a 7500 Real-Time PCR System (Applied Biosystems, Foster,
CA, USA) using the following cycling parameters: 2 min at 50uC;
10 min at 95uC; 40 cycles of 15 s at 95uC, 30 s at 50uC; and 1 min
at 60uC (for set 1a, 1b, and 3a) or 15 s at 95uC and 1 min at 60uC
(for set 2a, 2b, and 2c).
Real-time PCR performance tests
Real-time PCR precision was assessed by testing three randomly
selected clinical samples. Sixteen replicates of each sample were
analyzed on three different days (n=48).
Analytical sensitivity was investigated using the genotype 1b
OptiQuantH HCV RNA Quantification Panel (Acrometrix,
Benicia, CA, USA). The lower limit of detection was determined
as the lowest concentration needed to provide genotype identifi-
cation with a hit rate of at least 95% of 24 replicates. The panel
member containing 5,000 IU/ml was diluted in negative human
plasma to 1,000, 500, 250, and 125 IU/ml. Relative sensitivity
was determined for genotypes 1a, 2b, and 3a by analyzing 8
replicates of clinical specimens. Based on the HCV viral load
assigned by the Cobas AmplicorH HCV Test (version 2.0; Roche,
Branchburg, NJ, USA), each specimen was diluted to 500, 250,
and 125 IU/ml. Eight replicates of each dilution were analyzed.
Specificity was assessed by testing 53 samples from healthy,
HCV-negative blood donors provided by the Blood Bank from
Clinics Hospital of University of Sa ˜o Paulo.
To assess analytical specificity and possible false-positive
detection by the genotype-specific primer-probe sets, we tested
specimens infected with Hepatitis B Virus (n=10), Hepatitis A
Virus (n=10), HIV (n=10), and dengue virus (n=10), which
belongs to the same family (Flaviviridae) as HCV. HIV-infected
samples were chosen because of the presumed high incidence of
HIV-HCV co-infection in the population studied. Those samples
tested negative for HCV RNA in the AmplicorH HCV Test
(version 2.0; Roche). We also included samples infected with
genotypes 4a (4 samples) and 5a (1 sample) to test for cross-
amplification and detection with genotypes 1, 2 and 3.
In vitro mixed infection
To determine whether the presence of hypothetical mixed
infections interfered with the specificity of the assay, we artificially
mixed different proportions of HCV RNA from different
genotypes. One sample of genotype 1a (550,000 IU/ml) and a
sample of genotype 3a (559,000 IU/ml) were mixed in proportions
of 1:1, 1:5, and 1:10 for 1a and 3a and vice-versa.
One-step real-time PCR
Reactions were performed with the same concentrations of
reagents and cycling parameters described above, with a final
reaction volume of 50 ml, except that the reaction mix was
prepared in a single fraction rather than two.
Partial sequencing of HCV NS5B region
Partial NSB5 sequencing was performed for 146 of the 304
specimens to verify the accuracy of the HCV genotypes
determined by the triplex HCV genotype PCR reactions. Reverse
transcription was performed essentially as previously described
[22] using 300 U of Moloney Murine Leukemia Virus RT
(MMLV-RT; Invitrogen) and 7.5 ng/ml of random primer (cat. #
48190-011; Invitrogen).
Primers NS5B2F (59-TTCACGGAGGCTATGACY
C/TAGG-
39) and NS5B-2R (59-CGGGCATGM
A/CGACAS
G/CGCTGT-
GA-39), located between the positions 1683 and 1704 of the NS5B
region, were used for partial sequencing of the NS5B region
generating an expected product of 688 bp. Each PCR reaction
contained buffer [10X concentrations: 200 mM Tris-HCl
(pH 8.4), 500 mM KCl], 1.5 mM MgCl2, 200 nM of each dNTP,
1 mM of each primer, 2.5 IU of High Fidelity Taq DNA
Table 2. Primers and Probes used in Real-Time PCR genotyping of NS5B region.
Primer Genotype Sequences (59-39) Product Position
1
F56_1–3 1 and 3 59-CACACTCCAGTY
C/TAAY
C/TTCCTGG-39 241 bp 1204–1224
R56 1–3 59-CW
A/TM
A/CCTGGAGAGTAACTGTGGAG-39 1444–1423
GEN2FSN 2 59-GAC ACT CCC CTG TCA ATT CW
A/TTG G - 3 9 120 bp 1202–1224
GEN2RSN 59-TG GTY
C/T CAG AGT GTC Y
C/TTG GGC-39 1321–1313
Probe Genotype Fluorophore Sequences Quencher Position
1
1a66 1a 6-FAM 59-CAGCTTGAACAGGC-39 NFQ-MGB 1312–1325
1b266 1b VIC 59-CAACTTGAAAAAGC-39 NFQ-MGB 1312–1325
3a66 3a NED 59-AGATACTTGATCGACCC-39 NFQ-MGB 1312–1325
2a 2a NED 59-TTCTCCATTCTCAT-39 NFQ-MGB 1287–1300
2b 2b 6-FAM 59-TTCTCCATACTATT-39 NFQ-MGB 1287–1300
2c 2c VIC 59-TTCTCCGTCTTGAT-39 NFQ-MGB 1287–1300
11a_.H77.NC_004102–reference sequence used to calculate positions of NS5B region.
doi:10.1371/journal.pone.0010150.t002
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volume was adjusted to 50 ml using ultrapure water. PCR was
carried out using a GeneAmp PCR System 9700 (Applied
Biosystems). The following amplification conditions were used:
5 min at 94uC; 35 cycles at 95uC for 30 s, 60.5uC for 1 min for
primers NS5B2F/NS5B2R or 56uC for 45 s for primers F56_1–3/
R56_1–3 (Table 2), 72uC for 1 min; 10 min at 72uC and a final
hold at 10uC.
Sequencing reactions were performed in both directions using
the Big Dye terminator technology (version 3.2; Applied
Biosystems) and products were detected with an ABI 3130 Genetic
Analyzer (Applied Biosystems). Sequencing analysis was per-
formed using SeqScape (Applied Biosystems), and genotypes were
assigned by matching using Blast (http://blast.ncbi.nlm.nih.gov/
Blast.cgi).
The generated sequences were submitted to GenBank and can
be retrieved under accession numbers FJ159697 to FJ159849.
Phylogenetic analysis
An internal fragment of 216 nucleotides within the PCR
products generated for sequencing (positions 1223–1438 in the
NS5B region according to the reference sequence H77, GenBank
accession number NC004102) was used for phylogenetic analysis.
Nucleotide distances were computed on MEGA version 4.0 [23]
by the r-distance algorithm and phylogenetic trees were inferred
using the neighbor joining method. Robustness of tree branches
was tested by bootstrap analysis (1000 replicates).
Statistical analysis
Consistency between real time PCR and LiPA was assessed
using the k coefficient, with k values between 0.61 and 0.80 taken
to indicate good concordance [24], when both methods classified
specimens into the same categories (genotypes or subtypes).
Statistical analysis was performed using Program R for Windows
(version 2.7.0). Concord software was used to calculate agreement
between techniques. A P value of less than 0.05 was considered
significant.
Unitary test cost estimation
Estimation of unitary test costs was based on the currently
available commercial reagent prices in Brazil at the time the study
was conducted. Equipment maintenance, human resources and
other indirect costs were not taken into account for comparison
and calculation.
To estimate the unitary cost of the real-time PCR test, costs of
NucliSens EasyMAG extraction kit (bioMerieux), Superscript
TM
III Platinum One-Step qRT-PCR kit for 500 reactions (Invitro-
gen), TaqMan probes (synthesized by Applied Biosystems), primer
sets (synthesized by Invitrogen), RNase Out (Invitrogen), and
optical tubes and caps (Applied Biosystems) were taken for
comparison. Assessment of the final costs related to LiPA v.1
included the AmplicorH Hepatitis C Vı ´rus–HVC–Test, version 2.0
(Roche) and the VERSANT
TM HCV Genotype Assay-LiPA v.1
(Siemens).
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